Dishman Of India Rejects World Bank Financing For Planned Expansion
This article was originally published in PharmAsia News
Executive Summary
India's Dishman Pharmaceuticals says it has rejected World Bank conditions for new financing for the firm, opting instead to try other means to raise funds to support its expansion plans. Medical Director J.R. Vyas said his company did not like the World Bank conditions. Funds are needed to support Dishman's five-year expansion plan that include developing new products and building new facilities in India and China. The firm also plans to strengthen its subsidiaries and enter into various joint ventures. (Click here for more
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.